Merck & Co. Inc. (MRK)

75.83
0.04 0.05
NYSE : Health Technology
Prev Close 75.87
Open 75.57
Day Low/High 75.36 / 76.20
52 Wk Low/High 52.83 / 80.19
Volume 10.07M
Avg Volume 13.34M
Exchange NYSE
Shares Outstanding 2.60B
Market Cap 197.29B
EPS 0.90
P/E Ratio 60.70
Div & Yield 2.20 (2.63%)

Latest News

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Merck's KEYTRUDA® (pembrolizumab) Reduced Risk Of Death By 31 Percent Compared To Chemotherapy In Previously Treated Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Merck's KEYTRUDA® (pembrolizumab) Reduced Risk Of Death By 31 Percent Compared To Chemotherapy In Previously Treated Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the second-line treatment of...

Moderna Shares Jump on Positive Cancer-Treatment Progress

Moderna Shares Jump on Positive Cancer-Treatment Progress

Report on positive results of new drugs to treat ovarian and other cancers sends shares higher.

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Jim Cramer talks about the Fed, and outlines your game plan.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Merck Is My Top Stock Pick for 2019

Merck Is My Top Stock Pick for 2019

People will still take their medicine regardless of the state of the economy.

Merck's KEYTRUDA® (pembrolizumab) Receives Five New Approvals In Japan, Including In Advanced Non-Small Cell Lung Cancer (NSCLC), As Adjuvant Therapy For Melanoma, And In Advanced Microsatellite Instability-High (MSI-H) Tumors

Merck's KEYTRUDA® (pembrolizumab) Receives Five New Approvals In Japan, Including In Advanced Non-Small Cell Lung Cancer (NSCLC), As Adjuvant Therapy For Melanoma, And In Advanced Microsatellite Instability-High (MSI-H) Tumors

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that KEYTRUDA, Merck's anti-PD-1 therapy, has simultaneously received five new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA), including...

Merck Exercises Option For NGM Bio's Investigational Insulin Sensitizer, NGM313, For The Treatment Of NASH And Type 2 Diabetes

Merck Exercises Option For NGM Bio's Investigational Insulin Sensitizer, NGM313, For The Treatment Of NASH And Type 2 Diabetes

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc.

Pfizer Could Be a Healthy Option in This Volatile Market

Pfizer Could Be a Healthy Option in This Volatile Market

The health care sector may a good place to weather this storm. Here is why and how to play it.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Merck To Participate At The 37th Annual J.P. Morgan Healthcare Conference

Merck To Participate At The 37th Annual J.P. Morgan Healthcare Conference

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

The New #64 Most Shorted S&P 500 Component: Merck

The New #64 Most Shorted S&P 500 Component: Merck

The most recent short interest data has been released for the 12/14/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck KGaA, Darmstadt, Germany, And Pfizer Provide Update On JAVELIN Ovarian 100 Trial Of Avelumab In Previously Untreated Advanced Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Provide Update On JAVELIN Ovarian 100 Trial Of Avelumab In Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany, and NEW YORK, December 21, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, and Pfizer Inc.

Merck Provides Update On KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) For KEYNOTE-042 Trial

Merck Provides Update On KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) For KEYNOTE-042 Trial

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights To Intrexon

Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights To Intrexon

DARMSTADT, Germany, December 20, 2018 /PRNewswire/ -- Not intended for UK-based media   Agreement enables Merck KGaA, Darmstadt, Germany, to maintain an investment in the rapidly advancing oncology field of CAR-T , while focusing its R&D efforts  Intrexon...

LYNPARZA® (olaparib) Meets Primary Endpoint In Phase 3 SOLO-3 Trial For The Treatment Of Relapsed BRCA-Mutated Advanced Ovarian Cancer

LYNPARZA® (olaparib) Meets Primary Endpoint In Phase 3 SOLO-3 Trial For The Treatment Of Relapsed BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the randomized, open-label, controlled, Phase 3 SOLO-3 trial of LYNPARZA tablets in 266 patients with relapsed ovarian cancer after...

TheStreet Quant Rating: A- (Buy)